Community Stories & Education
Life Through a Different Lens: They Just Talked About Eyes!
Christine and Anthony Gonzales dreamed of having a large family and were thrilled when their first child, Iliana, was born in August 2018. However, within a few months, their excitement turned to concern. “About a week after Iliana received her…
Most Recent
Promising RNA Therapies for LCA10 and USH2A Move Back into Clinical Trials
Moving emerging therapies through clinical trials and across the finish line is often challenging—and in some cases, harrowing. Many treatments…
Testing the Limits: What is your Kilimanjaro?
Throughout my life, I’ve pushed my body to do some incredible things—from wrestling in high school to running a marathon…
My Friend Luca: Balancing Hope and Reality
Three-year-old Luca Corso’s preschool teacher announced that everyone should quickly sit on their floor shapes for carpet time. As the…
Reports on Gene Therapy Advances: A Highlight from the 2025 Hope in Focus Conference in Minneapolis
Gene therapy is unequivocally the most advanced approach for treating retinal diseases like Leber congenital amaurosis (LCA). Of course, there’s LUXTURNA® which is…
Diverse Emerging Therapies Featured at the 2025 Hope in Focus Conference in Minneapolis
The development of diverse treatment approaches for Leber congenital amaurosis (LCA) is necessary because no single modality will work for everyone affected….
Living with IRDs: Insights and Inspiration from the Front Lines
The 2025 LCA Family Conference in Minneapolis, MN, offered four informational panel sessions, where the 135 attendees learned about living…
Moving Forward: Understanding More about Clinical Trials
The second panel session of the 2025 LCA Family Conference, “Participating in a Clinical Trial,” examined clinical trial development and…
FROM THE WALL: Pushing Boundaries, Building Confidence
Throughout her 29 years, Michelle Ward Caton has embraced life with unwavering curiosity and gusto. Determined to test her abilities…
BlueRock Photoreceptor Replacement Therapy Moving into a Clinical Trial
The development of gene therapies for inherited retinal diseases (IRDs) took off when young adults and children showed significant vision…
LCA Research Updates from FFB
BlueRock Photoreceptor Replacement Therapy Moving into a Clinical Trial
The development of gene therapies for inherited retinal diseases (IRDs) took off when young adults and children showed significant vision improvements in an early clinical trial.
Foundation Fighting Blindness and CheckedUp® Partner to Educate Retinal-Disease Patients About Research, Resources, and Emerging Therapies During Doctor Visits
The Foundation Fighting Blindness (the Foundation) and CheckedUp have formed a collaborative partnership to deliver patient-friendly diagnostic and disease-management information to people with retinal diseases such as age-related macular degeneration, retinitis pigmentosa, and Stargardt disease during their visits to eye doctors.
A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies
AN EMERGING, vision-restoring gene therapy for a devastating retinal disease is poised for Food and Drug Administration (FDA) approval. If it gets the regulatory nod, it will be the first gene therapy to receive FDA approval for the eye or an inherited condition.